Track topics on Twitter Track topics that are important to you
Bedfordshire, UK, 26 March 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, today announced that it has initiated early validation of COVID-19 point-of-need diagnostic tests with the Liverpool School of Tropical Medicine and St Georges’ University London.
The availability of fast, reliable diagnostics for COVID-19 has been identified as one of the critical opportunities to support the control of the pandemic and “flatten the curve” of cases worldwide.
The accelerated development of the test has been made possible by funding from UK Aid, as part of the £46 million the UK government has announced so far for international coronavirus (COVID-19) prevention and research.
Mologic’s early prototypes of antibody tests have made it possible to begin a process of optimisation. Leading laboratories on each continent will evaluate these different prototypes to independently assess their performance.
While the assessment and optimisation will be expedited, it is vital that any prototype device for COVID-19 is subject to rigorous validation before it is made available for use in the global pandemic response.
Following rapid assessments in the UK, the technology will be shipped to global validation partners including the Institut Pasteur de Dakar in Senegal, La Jolla Institute for Immunology in the United States, the Wuhan Institute of Virology in China, the University of Malaya in Malaysia, the Institute for Health Science Research Germans Trias I Pujol (IGTP) in Spain, and the Oswaldo Cruz Foundation (Fiocruz) in Brazil.
Once ready, the device will allow users to test for exposure to the virus at home, in the community, or in the clinic, providing a result within 10 minutes, without the need for special training, electricity or a laboratory. The company is working in close partnership with the Institut Pasteur de Dakar to validate the COVID-19 test and manufacture at diaTROPiX, a new facility in Senegal. This will be the first time that a diagnostic kit created in the UK will be jointly manufactured in Africa, ensuring tests are available in settings with limited access to laboratory facilities.
Mologic has taken the decision to sell the diagnostic test at cost to low-income settings to ensure affected countries have access to the kits during the global emergency. This will allow high-quality diagnostics to be produced in low-income settings with the aim of ensuring that the test is available to all.
Professor Paul Davis, Co-Founder and Chief Scientific Officer, Mologic, commented: “Completion of the first prototypes is a significant step in Mologic’s development of a rapid diagnostic test for COVID-19 and we are proud of our team’s achievement in reaching this point so quickly, while maintaining the most rigorous standards. Diagnostics are a critical weapon in the fight against this pandemic and, once ready, this test will enable affordable, more accurate and earlier diagnosis of infection, limiting the spread of the disease.”
Dr Joe Fitchett, Medical Director, Mologic, said: “Until a vaccine is ready or a medicine is proven to be effective, we need to decentralise diagnostics to the community as quickly as possible. Properly assessing new tests during an epidemic is a critical and necessary step to ensuring access to the technology. Mologic’s prototypes will now be subject to international validation, with leading labs across the world.”
International Development Secretary Anne-Marie Trevelyan, said: “The UK has been at the heart of the global response to the coronavirus outbreak, investing heavily in the research and development of potential new tests and vaccines, including the work of world-class scientists across the UK. It is enormously encouraging to see the progress the British based lab Mologic, funded by UK aid, has already made to develop a reliable test for the virus, for use in the UK and around the world.”
Dr Emily Adams, Senior Lecturer in Diagnostics for Infectious Disease, Liverpool School of Tropical Medicine, commented: “We are extremely pleased to be working alongside Mologic and diaTROPiX on the evaluation and validation of rapid diagnostic tests for COVID-19. These tests could be a game changer for diagnosis and follow-up of patients both in hospital and in the community, allowing us to detect cases early and isolate patients and their families rapidly. Of course in low-resource settings, where we are starting to see cases, these are the only tests that are appropriate for use. We need to manufacture and deliver as soon as we possibly can”
Notes to Editors
Complete list of validation partners:
· Liverpool School of Tropical Medicine, London
· St Georges University London, London
· Institut Pasteur de Dakar, Senegal
· La Jolla Institute for Immunology in the United States
· Wuhan Institute of Virology, China
· University of Malaya, Malaysia
· Institute for Health Science Research Germans Trias i Pujol (IGTP), Spain
· Oswaldo Cruz Foundation (Fiocruz), Brazil
Sarah Jeffery, Zyme Communications
+44 (0)7771 730919
Jim Calverley, Global Health Strategies
+44 (0)7810 805092
Clare Bebb, The Liverpool School of Tropical Medicine
+44 (0)151 705 3135
Carl Alexander, St George's, University of London
About Mologic www.mologic.co.uk
Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company works with global organisations, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-need. Mologic’s founder, Professor Paul Davis, was the originator of the Clearblue pregnancy test that was launched in 1988 as the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since its formation in 2003.
Mologic offers world-leading technology and scientific research expertise for contract research and development, alongside a portfolio of device and reagent products for clinical and commercial applications. The Company also helps organisations to scale-up manufacturing from initial prototyping through low to mid-scale production.
Mologic’s science has broad application across markets and disease states where rapid, accurate point-of-need testing can help make a difference in patient care and patient outcomes.
Clients include the Bill & Melinda Gates Foundation where Mologic is leveraging core technology through its Centre for Advanced Rapid Diagnostics (CARD) to develop the next-generation of ultra-sensitive point-of-need diagnostics which are easy to use and low cost to manufacture - critical to the success of many global health programmes.
The Company is actively seeking strategic partners for its internal pipeline of respiratory, infectious disease and women’s health diagnostics.
Mologic is headquartered in Bedford in the United Kingdom and has a US subsidiary in the greater Boston area, MA, USA.
diaTROPiX is a joint initiative currently supported by 4 core members (Fondation Mérieux, the Foundation for Innovative and New Diagnostics, Institut de Recherche pour le Développement & Institut Pasteur de Dakar) and two technology transfer partners (Mologic and bioMérieux).
Tropical Medicine is the study of diseases more commonly found in tropical regions than elsewhere. Examples of these diseases are malaria, yellow fever, Chagas disease, Dengue, Helminths, African trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic filaria...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...